Prenatalsafe® NIPT is a non-invasive prenatal test that enables the analysis of fetal genetic material from a routine blood sample taken from the mother. Depending on the test chosen, it allows for the screening of aneuploidies, microdeletion syndromes and single gene disorders.
Prenatalsafe® is offered by the Eurofins Genoma Group laboratories with an option to choose from 9 levels of prenatal screening, each with a different level of detail.
Prenatalsafe® is the most technologically advanced non-invasive prenatal test currently available:
Simple
- Just a blood sample (8-10 ml) from the pregnant woman
Safe
- Prenatalsafe® is a NON-INVASIVE screening test: safe for the mother and the fetus
- Reduces the risk of abortion-related to traditional invasive prenatal diagnosis techniques, such as amniocentesis and Chorionic villus sampling (CVS).
Reliable
- Concordance of the test for trisomy 13, trisomy 18 and trisomy 21 is 99.9% for singleton pregnancies (Pertile et al., 2021)
Fast
- Prenatalsafe® results can be available from 3 working days.
By analysing the cell-free fetal DNA (cfDNA) circulating in the mother's blood, this new non-invasive prenatal test is able to screen fetal karyotype and serious genetic diseases in the fetus.
Prenatalsafe® can be combined with the RhSafe® test, a non-invasive prenatal examination that, by analysing fetal DNA isolated from a blood sample of the pregnant woman, allows to determine the Fetal Rh(D) factor. The RhSafe® test is optional and is performed on request in case of Rh(D) negative pregnant women with Rh(D) positive partner.
Prenatalsafe® 3 & 5 screens will be processed in the UK by Eurofins Clinical Diagnostics, 90 Priestley Road, Surrey Research Park, Guildford GU2 7AU. All other screens will be referred to Genoma Labs, Italy.